Capital Performance Advisors’s Altimmune ALT Stock Holding History

Capital Performance Advisors’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11	Closed	-$68	–	277
2024 Q3	$68	Buy	+11	New	+$75	﹤0.01%	2759

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capital Performance Advisors's ALT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Altimmune (ALT) in Q4 2024, closing a stake of 11 shares — an estimated $68 sold.

Capital Performance Advisors first reported a position in ALT in Q3 2024 and held it in 1 quarter. The position peaked at $68 in Q3 2024. 182 funds tracked by Wall St. Rank hold ALT as of Q4 2024.

Capital Performance Advisors reported no remaining Altimmune position as of Q4 2024 after selling out during the quarter.
Capital Performance Advisors sold 11 Altimmune shares in Q4 2024, an estimated $68.
Capital Performance Advisors first reported a position in Altimmune in Q3 2024 and held it in 1 quarter.
Capital Performance Advisors's Altimmune position peaked at $68 in Q3 2024.
182 funds tracked by Wall St. Rank held Altimmune as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.